ARVCNext™
Use
ARVCNext™ is a targeted panel for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Often, ARVC is asymptomatic and sudden death is the first symptom. Genetic testing with ARVCNext™ may effectively identify at-risk individuals or confirm a diagnosis, providing clarity on diagnosis, risk for sudden cardiac arrest, and guide management and prevention strategies tailored to patients with or at risk of ARVC.
Special Instructions
We offer family variant testing for all blood relatives of patients who undergo full single gene sequencing, multigene panel testing, or exome sequencing at Ambry Genetics and are found to have a pathogenic or likely pathogenic variant, at no additional cost within 90 days of the original report date. Family testing services are available only to patients receiving medical care in the U.S or US territories.
Limitations
The ARVCNext test is designed to detect >99% of described mutations in its target genes (analytical sensitivity). Clinical sensitivity may vary widely according to specific clinical and familial history. Gross deletion/duplication does not achieve exon-level resolution for every gene. Sanger sequencing confirms variants with insufficient coverage or interference, such as pseudogene influence or insufficient variant frequency.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided